Explore: Biotech · Drug Discovery · Diagnostics · Seed · Series A
Servier Ventures
Servier
Investment Thesis
Early-stage biotech investment in oncology and neurology, focusing on late preclinical assets where Servier can provide scientific, clinical, industrial expertise and network access. Strategic fund aligned with Servier's drug development capabilities.
About Servier Ventures
Servier Ventures is a €200m ($234m) corporate venture capital fund launched by French pharmaceutical company Servier to invest in early-stage biotech startups. The fund targets oncology and neurology-focused companies, initially in Europe, with plans to expand to the US and Asia. It aims to bridge the funding gap between early-stage research and late-stage development activities.
Sectors
Stages
Geographic focus
Notable Investments
Cytospire Therapeutics
Verified 29 April 2026 · Sources: company website, Fusion42 review
Frequently asked questions
- What does Servier Ventures invest in?
- Servier Ventures invests in Biotech, Drug Discovery and Diagnostics at the seed and series-a stages.
- Which geographies does Servier Ventures focus on?
- Servier Ventures focuses on Europe, and is headquartered in France.
- What is Servier Ventures's typical check size?
- Servier Ventures typically writes checks of $5.9M to $11.8M.